Summary of Key Points
U.S. President Donald Trump has announced a phased tariff policy targeting imported generic drugs: Starting from August 1, 2026, there will be a two-year zero-tax period to encourage companies to relocate their production back to the United States. After that, tariffs will gradually increase to 100% in the first year following the implementation (after August 2028) and 200% in the second year. The aim is to promote the return of generic drug production to U.S. shores. The impact of this policy on China's pharmaceutical exports is manageable in the short term (due to the low proportion of generic drugs exported and the buffer period), but long-term challenges must be addressed. However, there are uncertainties surrounding the implementation of the policy—the United States relies heavily on Chinese raw materials for medicines and inexpensive generic drugs, which could lead to adjustments due to factors such as rising drug prices and upcoming elections.
Detailed Analysis
1. Trump's Generic Drug Tariff Policy: A "Soft Start, Then a Hard Hit" Strategy
This policy is akin to offering an incentive before imposing a penalty:
- Buffer Period (2026.8–2028.8): Imported generic drugs will be exempt from tariffs for two years to give companies time to move their production facilities back to the U.S.
- Penalty Period: After the buffer period, tariffs will rise to 100% in the first year and 200% in the second year—meaning that companies that do not relocate will face significant costs that may make it difficult for them to sell their products.
- Exceptions: Patented drugs, branded drugs, and innovative drugs are not affected by this policy, as these are areas where the U.S. has a competitive advantage, and the policy is intended to maintain its effectiveness in these sectors.
The primary goal is clear: to bring generic drug production back to the U.S., create jobs, and reduce reliance on foreign supply chains.
2. China's Pharmaceutical Exports to the U.S.: Raw Materials Are the Main Focus
Among the pharmaceutical products China exports to the U.S., raw materials for manufacturing drugs constitute the majority:
- 2025 Data: The value of raw material exports was 3.5 times that of formulated drug exports; specifically, raw material exports to the U.S. amounted to $4.07 billion, while formulated drug exports were only $1.162 billion.
- Proportion of Generic Drugs: The share of generic drugs in China's exports to the U.S. is relatively low, and innovation-driven drugs are mainly part of service trade agreements (e.g., assisting American companies with research and development).
- Market Distribution: India (6.26 billion) and the U.S. (4.07 billion) are the two largest markets for Chinese raw material exports; formulated drug exports are primarily directed to the European Union (41.06%), with the U.S. accounting for only 13.14%.
Therefore, the impact of this policy on China's generic drug exports to the U.S. is limited at present.
3. Impact on China's Pharmaceutical Exports: Minimal Short-Term Pressure, Long-Term Challenges
- Short Term (2026–2028): With a zero-tax buffer period and a low proportion of generic drugs in exports, the impact is minimal.
- Long Term (After 2028): If tariffs rise to 100% or 200%, it will become difficult for Chinese generic drug manufacturers to sell their products in the U.S., either due to high costs or the need to establish production facilities there.
- Safety of Raw Material Supplies: Experts suggest that the U.S. cannot quickly replace its dependence on Chinese raw materials, as a disruption could lead to soaring drug prices and shortages. Therefore, this aspect is not a major concern for China.
- Response Strategies: Generic drug companies can plan ahead by either setting up production facilities in the U.S. or shifting their markets to the European Union, which accounts for 41% of China's formulated drug exports.
4. Uncertainties in Policy Implementation: Elections and Drug Prices May Mitigate the Impact
There are many variables that could affect the actual implementation of this policy:
- Elections: The tariff increase is scheduled to begin in August 2028, coinciding with the U.S. presidential elections, which could result in a new administration overturning the current policy.
- Flexibility in the Observation Period: The White House has set a one-year observation period, so the tariffs are not set in stone; they could be postponed if there are shortages of drugs or diplomatic considerations.
- Risk of Public Protest: The U.S. healthcare system relies on inexpensive imported generic drugs, and if higher tariffs lead to price increases, public backlash is likely. As a result, the government may introduce exemptions for essential medications.
In summary, this policy is more of a threat than a strict enforcement measure, with its actual impact likely being mitigated by various factors.
5. The U.S.'s Dilemma: Desire to Re-localize Production, Yet Dependence on Inexpensive Imports
Trump's policy seems tough, but the U.S. faces a dilemma:
- Desire for Re-localization: The U.S. wants to produce generic drugs domestically to create jobs and reduce reliance on foreign countries.
- Dependence on Imports: Chinese and Indian generic drugs and raw materials are cheaper; raising tariffs to 200% would significantly increase drug costs, leading to higher healthcare expenses and public dissatisfaction. Additionally, a disruption in raw material supplies could disrupt domestic production.
Therefore, the U.S. government is unlikely to fully enforce the policy; it is more of a tactic to pressure companies to relocate their production rather than a complete ban on imports.
Conclusion
The impact of this policy on China's pharmaceutical exports is relatively minor in the short term. In the long run, Chinese generic drug companies will need to adapt. However, due to the U.S.'s own dependence on imported goods, the policy is unlikely to be fully implemented. Chinese companies should take advantage of the buffer period to make strategic moves, such as establishing production facilities in the U.S. or expanding into other markets like the European Union, without excessive concern.